Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 5/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551908 | 0.92 | PLK1 (0.36) | PLK1MAPK14RPS6KB1IDH1AR | |
| SCHEMBL3556289 | 0.90 | PLK1 (0.39) | PLK1MAPK14RPS6KB1IDH1AR | |
| SCHEMBL3546243 | 0.89 | MAPK1 (0.33) | PLK1MAPK14RPS6KB1IDH1IGF1R | |
| SCHEMBL27691888 | 0.88 | PLK1 (0.34) | PLK1MAPK14RPS6KB1 | |
| SCHEMBL3546245 | 0.88 | IKBKB (0.35) | PLK1MAPK14RPS6KB1IDH1IGF1R | |
| SCHEMBL3546784 | 0.87 | PLK1 (0.45) | PLK1MAPK14RPS6KB1IDH1AR | |
| SCHEMBL3549665 | 0.87 | CDK1 (0.40) | PLK1MAPK14CDK1KDR | |
| SCHEMBL3560349 | 0.87 | PLK1 (0.40) | PLK1MAPK14RPS6KB1IDH1AR | |
| SCHEMBL3557833 | 0.86 | PLK1 (0.37) | PLK1RPS6KB1IDH1IGF1RCDK2 | |
| SCHEMBL3549400 | 0.86 | PLK1 (0.39) | PLK1MAPK14RPS6KB1ARCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101048406-B | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| CN-101048406-A | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-10-03 | — | — | CN | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | PLK1 1/4885MAPK14 680/4885RPS6KB1 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.